|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020291,
umls-concept:C0020933,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0066005,
umls-concept:C0389169,
umls-concept:C0456387,
umls-concept:C0597979,
umls-concept:C1521991,
umls-concept:C1979963,
umls-concept:C2003903
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-12-21
|
|
pubmed:abstractText |
The stability of doripenem to hydrolysis by beta-lactamases from molecular classes A to D was compared to the stability for imipenem and meropenem. Doripenem was stable to hydrolysis by extended-spectrum beta-lactamases and AmpC type beta-lactamases and demonstrated high affinity for the AmpC enzymes. For the serine carbapenemases SME-3 and KPC-2 and metallo-beta-lactamases IMP-1 and VIM-2, doripenem hydrolysis was generally 2- to 150-fold slower than imipenem hydrolysis. SPM-1 hydrolyzed meropenem and doripenem fourfold faster than imipenem.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-10103197,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-12543663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-14638498,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-15047535,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-15047550,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-15273124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-16048978,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-16319181,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-16446375,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-17005839,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-17591851,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-18594288,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-18779357,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-3873900,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-4202581,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-6979307,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-6982680,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-7574506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19884379-8787910
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1098-6596
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
565-9
|
|
pubmed:dateRevised |
2010-9-28
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
|
|
pubmed:affiliation |
Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202 South, Raritan, NJ 08869, USA. aqueenan@its.jnj.com
|
|
pubmed:publicationType |
Journal Article
|
